190 related articles for article (PubMed ID: 34894110)
1. Improved cognitive function in patients with major depressive disorder after treatment with vortioxetine: A EEG study.
Kim H; Baik SY; Kim YW; Lee SH
Neuropsychopharmacol Rep; 2022 Mar; 42(1):21-31. PubMed ID: 34894110
[TBL] [Abstract][Full Text] [Related]
2. Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine.
Nierenberg AA; Loft H; Olsen CK
J Affect Disord; 2019 May; 250():35-42. PubMed ID: 30826492
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of vortioxetine in patients with major depressive disorder and co-morbid generalized anxiety disorder in routine clinical practice: A subgroup analysis of the RELIEVE study.
Almeida SS; Christensen MC; Simonsen K; Adair M
J Psychopharmacol; 2023 Mar; 37(3):279-288. PubMed ID: 36377523
[TBL] [Abstract][Full Text] [Related]
4. Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder.
Inoue T; Sasai K; Kitagawa T; Nishimura A; Inada I
Psychiatry Clin Neurosci; 2020 Feb; 74(2):140-148. PubMed ID: 31725942
[TBL] [Abstract][Full Text] [Related]
5. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study.
Baune BT; Sluth LB; Olsen CK
J Affect Disord; 2018 Mar; 229():421-428. PubMed ID: 29331703
[TBL] [Abstract][Full Text] [Related]
6. Assessment in Work Productivity and the Relationship with Cognitive Symptoms (AtWoRC): primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD).
Chokka P; Bougie J; Rampakakis E; Proulx J
CNS Spectr; 2019 Jun; 24(3):338-347. PubMed ID: 29792585
[TBL] [Abstract][Full Text] [Related]
7. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study.
Chokka P; Bougie J; Proulx J; Tvistholm AH; Ettrup A
CNS Spectr; 2019 Dec; 24(6):616-627. PubMed ID: 30802419
[TBL] [Abstract][Full Text] [Related]
8. Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram.
Levada OA; Troyan AS
J Affect Disord; 2019 May; 250():114-122. PubMed ID: 30852363
[TBL] [Abstract][Full Text] [Related]
9. The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram.
Vieta E; Sluth LB; Olsen CK
J Affect Disord; 2018 Feb; 227():803-809. PubMed ID: 29673132
[TBL] [Abstract][Full Text] [Related]
10. Distinct association of plasma BDNF concentration and cognitive function in depressed patients treated with vortioxetine or escitalopram.
Sagud M; Nikolac Perkovic M; Dvojkovic A; Jaksic N; Vuksan-Cusa B; Zivkovic M; Kusevic Z; Mihaljevic-Peles A; Pivac N
Psychopharmacology (Berl); 2021 Jun; 238(6):1575-1584. PubMed ID: 33560444
[TBL] [Abstract][Full Text] [Related]
11. Association between cognitive function and performance on effort based decision making in patients with major depressive disorder treated with Vortioxetine.
Subramaniapillai M; Mansur RB; Zuckerman H; Park C; Lee Y; Iacobucci M; Cao B; Ho R; Lin K; Phan L; McIntyre RS
Compr Psychiatry; 2019 Oct; 94():152113. PubMed ID: 31404802
[TBL] [Abstract][Full Text] [Related]
12. The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials.
McIntyre RS; Harrison J; Loft H; Jacobson W; Olsen CK
Int J Neuropsychopharmacol; 2016 Jun; 19(10):. PubMed ID: 27312740
[TBL] [Abstract][Full Text] [Related]
13. Effect of vortioxetine in subjects with major depressive and alcohol use disorders: a 6-month retrospective analysis.
Di Nicola M; Pepe M; Panaccione I; Moccia L; Dattoli L; Molinaro M; Sani G; Janiri L; McIntyre RS
CNS Spectr; 2022 Feb; 27(1):73-81. PubMed ID: 32772956
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of vortioxetine in patients with major depressive disorder and comorbid Alzheimer's disease in routine clinical practice: An analysis of a post-marketing surveillance study in South Korea.
Cumbo E; Adair M; Åstrom DO; Christensen MC
Front Aging Neurosci; 2022; 14():1037816. PubMed ID: 36698860
[TBL] [Abstract][Full Text] [Related]
15. Vortioxetine improves physical and cognitive symptoms in patients with post-COVID-19 major depressive episodes.
Di Nicola M; Pepe M; Montanari S; Spera MC; Panaccione I; Simonetti A; Sani G
Eur Neuropsychopharmacol; 2023 May; 70():21-28. PubMed ID: 36808043
[TBL] [Abstract][Full Text] [Related]
16. Effect of Vortioxetine on Cognitive Impairment in Patients With Major Depressive Disorder: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Huang IC; Chang TS; Chen C; Sung JY
Int J Neuropsychopharmacol; 2022 Dec; 25(12):969-978. PubMed ID: 35981958
[TBL] [Abstract][Full Text] [Related]
17. Real-world clinical outcomes and treatment patterns in patients with MDD treated with vortioxetine: a retrospective study.
McDaniel BT; Cornet V; Carroll J; Chrones L; Chudzik J; Cochran J; Guha S; Lawrence DF; McCue M; Sarkey S; Lorenz B; Fawver J
BMC Psychiatry; 2023 Dec; 23(1):938. PubMed ID: 38093196
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder.
McIntyre RS; Florea I; Tonnoir B; Loft H; Lam RW; Christensen MC
J Clin Psychiatry; 2017 Jan; 78(1):115-121. PubMed ID: 27780334
[TBL] [Abstract][Full Text] [Related]
19. Using self-reported vocational functioning measures to identify employed patients with impaired functional capacity in major depressive disorder.
Murthy NV; Xu R; Zhong W; Harvey PD
J Affect Disord; 2020 Jan; 260():550-556. PubMed ID: 31539692
[TBL] [Abstract][Full Text] [Related]
20. Exploratory Analysis of the Effects of Celecoxib on Cognitive Function in Vortioxetine-Treated Patients With Major Depressive Disorder in the PREDDICT Study: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Sampson E; Mills NT; Hori H; Schwarte K; Hohoff C; Schubert O; Clark SR; Fourrier C; Baune BT
J Clin Psychiatry; 2023 Oct; 84(6):. PubMed ID: 37796652
[No Abstract] [Full Text] [Related]
[Next] [New Search]
